Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Salarius Pharmaceuticals is a biotechnology business based in the US. Salarius Pharmaceuticals shares (SLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Salarius Pharmaceuticals employs 16 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $2.42 |
|---|---|
| 52-week range | $1.07 - $13.46 |
| 50-day moving average | $1.91 |
| 200-day moving average | $4.29 |
| Wall St. target price | $70.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.38 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.42 from 2023-01-27
| 1 week (2023-01-23) | -15.09% |
|---|---|
| 1 month (2022-12-30) | 58.17% |
| 3 months (2022-10-28) | 19.21% |
| 6 months (2022-07-29) | 1,173.68% |
| 1 year (2022-01-28) | 462.79% |
|---|---|
| 2 years (2021-01-29) | 118.02% |
| 3 years (2020-01-30) | 2.65 |
| 5 years (2018-01-30) | 4.19 |
| Gross profit TTM | $-6,708,304 |
|---|---|
| Return on assets TTM | -40.33% |
| Return on equity TTM | -99.02% |
| Profit margin | 0% |
| Book value | $7.39 |
| Market capitalisation | $5.6 million |
TTM: trailing 12 months
We're not expecting Salarius Pharmaceuticals to pay a dividend over the next 12 months.
Salarius Pharmaceuticals's shares were split on a 1:25 basis on 16 October 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Salarius Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Salarius Pharmaceuticals shares which in turn could have impacted Salarius Pharmaceuticals's share price.
Over the last 12 months, Salarius Pharmaceuticals's shares have ranged in value from as little as $1.07 up to $13.4575. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Salarius Pharmaceuticals's is 0.8391. This would suggest that Salarius Pharmaceuticals's shares are less volatile than average (for this exchange).
Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
